Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: Ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 174-182

  Verbrugge, Sue Ellen ^a   Assaraf, Yehuda G ^c   Dijkmans, Ben A C ^a   Scheffer, George L ^b   Al, Marjon ^a   Den Uyl, Debby ^a   Oerlemans, Ruud ^a   Chan, Elena T ^d   Kirk, Christopher J ^d   Peters, Godefridus J ^b   Van Der Heijden, Joost W ^a   De Gruijl, Tanja D ^b   Scheper, Rik J ^b   Jansen, Gerrit ^a  

^a VUmc Institute for Cancer and Immunology V ICI   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BORTEZOMIB; CARFILZOMIB; CHYMOTRYPSIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; ONX 0912; ONX 0914; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESISTANCE; EX VIVO STUDY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FOLDING; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTATION; OLIGOPEPTIDES; P-GLYCOPROTEIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TREATMENT OUTCOME;

EID: 84858675332     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187542     Document Type: Article

References (40)

1. Agarwal V, Mittal SK, and Misra R (2009) Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Clin Rheumatol 28:427-433.
2. Bennett MK and Kirk CJ (2008) Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Dev 11:616-625.
3. Borgnia MJ, Eytan GD, and Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163-3171. (Pubitemid 26055617)
4. Bram EE, Adar Y, Mesika N, Sabisz M, Skladanowski A, and Assaraf YG (2009) Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2. Mol Pharmacol 75:1149-1159.
5. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, and Anderson KC (2010) A novel orally active proteasome inhibitor ONX0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116:4906-4915.
6. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383-6391. (Pubitemid 47037522)
7. Dick LR and Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15:243-249.
8. Elliott PJ, Zollner TM, and Boehncke WH (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81:235-245. (Pubitemid 36578922)
9. Eytan GD, Borgnia MJ, Regev R, and Assaraf YG (1994) Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein. J Biol Chem 269:26058-26065. (Pubitemid 24328413)
10. Gillet JP, Efferth T, and Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237-262. (Pubitemid 46899341)
11. Groll M, Berkers CR, Ploegh HL, and Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14:451-456. (Pubitemid 43363478)
12. Gutman D, Morales AA, and Boise LH (2009) Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia 23:2181-2183.
13. Hershko A and Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479. (Pubitemid 28411135)
14. Kisselev AF, Callard A, and Goldberg AL (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281:8582-8590. (Pubitemid 43847961)
15. Kloetzel PM (2004) The proteasome and MHC class I antigen processing. Biochim Biophys Acta 1695:225-233.
16. Lee SW, Kim JH, Park YB, and Lee SK (2009) Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 68:1761-1767.
17. Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, et al. (2010) Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst 102:1069-1082.
18. Lü S, Yang J, Chen Z, Gong S, Zhou H, Xu X, and Wang J (2009) Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/ leukemia cells derived from the Jurkat cell line. Exp Hematol 37:831-837.
19. Minderman H, Zhou Y, O'Loughlin KL, and Baer MR (2007) Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 60:245-255. (Pubitemid 46742540)
20. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15:781-787.
21. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, et al. (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14:748-755. (Pubitemid 351951516)
22. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489-2499.
23. Oerlemans R, van der Heijden J, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, et al. (2006) Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum 54:557-568. (Pubitemid 43228632)
24. Ogiso Y, Tomida A, and Tsuruo T (2002) Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase IIdirected drugs. Cancer Res 62:5008-5012. (Pubitemid 34984427)
25. Orlowski RZ and Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649-1657. (Pubitemid 351469448)
26. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, et al. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114:3439-3447.
27. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24:1506-1512.
28. Ruschak AM, Slassi M, Kay LE, and Schimmer AD (2011) Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103:1007-1017.
29. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, de Jong MC, Hooijberg JH, Mol CA, et al. (2000) Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269-5277.
30. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, Prozorovski T, Lange N, Steffen J, Rieger M, et al. (2010) Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142:613-624.
31. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, and Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers highlevel resistance to various hydrophilic antifolates. Cancer Res 65:8414-8422. (Pubitemid 41330608)
32. Sharma RC, Inoue S, Roitelman J, Schimke RT, and Simoni RD (1992) Peptide transport by the multidrug resistance pump. J Biol Chem 267:5731-5734.
33. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, and Trent JM (1991) Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63:923-929.
34. 11C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540-548.
35. van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, and Scheper RJ (2009) ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 86:1075-1087.
36. van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Schalkwijk CG, Scheffer GL, Scheper RJ, and Jansen G (2004) Development of sulfasalazine resistance in human T cells induces Expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα. Ann Rheum Dis 63:138-143. (Pubitemid 38122131)
37. van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, and Jansen G (2009) The proteasome inhibitor bortezomib inhibits the release of NFκB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 27:92-98.
38. Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, et al. (2002) Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62:1321-1331. (Pubitemid 35407456)
39. Zamora JM, Pearce HL, and Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454-462.
40. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, et al. (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52: 3028-3038.